KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Biogen (BIIB) over the last 16 years, with Q4 2025 value amounting to $807.2 million.

  • Biogen's Short-term Investments changed N/A to $807.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $807.2 million, marking a year-over-year change of. This contributed to the annual value of $807.2 million for FY2025, which is N/A changed from last year.
  • Biogen's Short-term Investments amounted to $807.2 million in Q4 2025.
  • In the past 5 years, Biogen's Short-term Investments registered a high of $3.5 billion during Q2 2023, and its lowest value of $97.6 million during Q3 2025.
  • Its 4-year average for Short-term Investments is $1.6 billion, with a median of $1.4 billion in 2021.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 3262.98% in 2021, then surged by 6437.19% in 2022.
  • Biogen's Short-term Investments (Quarter) stood at $1.5 billion in 2021, then fell by 4.39% to $1.5 billion in 2022, then skyrocketed by 134.85% to $3.5 billion in 2023, then tumbled by 76.67% to $807.2 million in 2025.
  • Its last three reported values are $807.2 million in Q4 2025, $97.6 million for Q3 2025, and $3.5 billion during Q2 2023.